Timothy Wyatt, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1811954407
Payments from drug & device makers
Across 165 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$454
- Sanofi-aventis U.S. LLC$349
- AstraZeneca$230
- Abbott$187
- Dexcom, Inc.$186
- Corcept Therapeutics$162
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,65298%
- Education$50%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $454 |
| Sanofi-aventis U.S. LLC | 21 | $349 |
| AstraZeneca | 13 | $230 |
| Abbott | 10 | $187 |
| Dexcom, Inc. | 11 | $186 |
| Corcept Therapeutics | 9 | $162 |
| Amgen | 8 | $138 |
| Boehringer Ingelheim | 8 | $122 |
| Xeris Pharmaceuticals, Inc. | 6 | $120 |
| Merck | 7 | $110 |
| Mannkind Corporation | 4 | $104 |
| Lilly USA, LLC | 6 | $103 |
| Insulet Corporation | 5 | $100 |
| Medtronic | 5 | $79 |
| Radius Health, Inc. | 4 | $63 |
| Shire North American Group Inc | 3 | $37 |
| Bayer | 2 | $31 |
| Sequel Med Tech, LLC | 2 | $30 |
| Alvogen Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Novartis | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Ascensia Diabetes Care US Inc. | 1 | $12 |
How this compares
$2,716 in reported general payments places this provider in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $443,739 |
| OzempicSemaglutide | 182 | $312,895 |
| MounjaroTirzepatide | 143 | $185,562 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 130 | $184,731 |
| JardianceEmpagliflozin | 127 | $162,717 |
| TrulicityDulaglutide | 73 | $104,039 |
| FarxigaDapagliflozin Propanediol | 64 | $65,063 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $63,401 |
| Teriparatide | 11 | $43,206 |
| RybelsusSemaglutide | 11 | $31,440 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $25,266 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $21,655 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $20,057 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $17,241 |
| Humalog Kwikpen U-100Insulin Lispro | 37 | $15,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $162 | $443,73911 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $454 | $347,614204 claims |
| Lilly USA, LLCMounjaro, Trulicity | $103 | $289,601216 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Synjardy | $122 | $226,878168 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $349 | $184,731130 claims |
| AstraZenecaFarxiga | $230 | $65,06364 claims |
| Alvogen IncTeriparatide | $20 | $43,20611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,225274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Senan SultanJacksonville$2.5M
- J EvansJacksonville$1.7M
- Wasim DeebJacksonville$1.5M
- Ricardo SilvaJacksonville$867K
- Anil ShresthaJacksonville$602K
- Joe ChehadeJacksonville$542K
- Firas WardaJacksonville$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.